Jin Yu

Jin Yu

Auto-generated profile, based on publicly available information

Jin Yu

Phase I Clinical Research Center, Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College Zhejiang Hangzhou China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
LWLei Wang
Lei Wang
QCQiang Cai
Qiang Cai
CFChaoqiang Fan
Chaoqiang Fan
WRWei Ren
Wei Ren
JYJin Yu
Jin Yu

13 November 2022 in Precision Medical Sciences
Verified
Journal Article
Open access
CHChunqi Huang
Chunqi Huang
YWYannan Wang
Yannan Wang
YWYi Wu
Yi Wu
SLSisi Lin
Sisi Lin
RHRui Hao
Rui Hao
YWYing Wang
Ying Wang
Voriconazole is a first‐line medicine for treating invasive fungal infections. We evaluated the pharmacokinetics (PK) and safety of single/multiple doses of voriconazole injection of Hailing Pharmaceutical Group (Test, T), an imitation of Vfend® (Reference, R). Healthy subjects (n = 36) randomly received a once‐daily dose of T or R 3 or 4 mg/kg on Day 1 (single dose), a once‐daily dose of T or R 6 mg/kg on Day 4, and then six consecutive days for twice‐daily doses of T or R 3 or 4 mg/kg (multiple doses). The plasma was collected up to 72 h at time points after dosing on Day 1/10. Samples were measured by the liquid chromatography tandem mass spectrometry method. PK parameters were confirmed according to a non‐compartmental model. The relationship between the PK profiles of T and R revealed the different behavior in 3‐ and 4‐mg/kg groups. After single/multiple doses in the 3‐mg/kg group, the mean value for the area under the plasma concentration–time curve (AUC0−t, AUC0−∞) of R is about twice T. However, there was a high degree of similarity in the 4‐mg/kg group. The maximum plasma concentration (Cmax) of T and R showed no noticeable difference in the two groups. The median Tmax of T and R were within 2.0–2.13 h in the 3‐mg/kg group and 2.0–2.17 h in the 4‐mg/kg group. Severe adverse events did not occur. No clinically significant differences were found in safety and tolerance between T and R. This clinical study indicated that voriconazole injection might provide a safer alternative medicine.